Tech-First Companies Take the Lead in AI Drug Discovery
BioPharmaceutical
Report


- Aug 15
- 7 min
Companies Making Automated Drug Discovery A Reality


- Feb 24
- 29 min
Artificial Intelligence in Drug Discovery and Biotech; 2022 Recap and Key Trends


- Mar 12, 2019
- 18 min
Anlysis of Bio - Pharma in East Asia - Trends Report


- Mar 12, 2019
- 5 min
Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide


- Mar 12, 2019
- 6 min
Spark's LCA2 gene therapy is likely to have greater benefit for younger patients


- Mar 12, 2019
- 5 min
Biosimilar Reference Products Expected to Grow


- Mar 12, 2019
- 4 min
Diabetic Neuropathy Patient Stratification, Chances Boosted


- Mar 12, 2019
- 6 min
J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom


- Mar 12, 2019
- 5 min
Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change


- Mar 12, 2019
- 6 min
The Unrealized Potential of Stem Cell Therapy


- Mar 12, 2019
- 5 min
*Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints


- Mar 12, 2019
- 5 min
*Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in tr


- Mar 12, 2019
- 4 min
*Merck's Phase III tecemotide vaccine trial in NSCLC in Asian patients could show benefit, but ..


- Mar 12, 2019
- 6 min
AstraZeneca’s pipeline projections a tough sell, Pfizer will struggle to drive combined value